Company Encyclopedia
View More
name
Shanghai RAAS
002252.SZ
Shanghai RAAS Blood Products Co., Ltd. engages in the manufacture and sale of blood products in China. It offers human serum albumin, human intravenous immunoglobulin, human coagulation factor VIII, human prothrombin complex, human fibrinogen, human thrombin and human fibrin adhesive, human immunoglobulin, hepatitis B immunoglobulin, tetanus immunoglobulin, and rabies immunoglobulin products. The company was founded in 1988 and is based in Shanghai, China.
1.579 T
002252.SZMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
BiotechnologyIndustry
Industry Ranking17/81
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE5.73%C
    • Profit Margin22.96%A
    • Gross Margin36.92%C
  • Growth ScoreC
    • Revenue YoY-4.67%D
    • Net Profit YoY-0.19%C
    • Total Assets YoY13.96%B
    • Net Assets YoY4.52%C
  • Cash ScoreC
    • Cash Flow Margin435.49%C
    • OCF YoY-4.67%D
  • Operating ScoreD
    • Turnover0.22D
  • Debt ScoreA
    • Gearing Ratio14.30%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Shanghai RAAS Blood Products Gets Trial Approval for Blood Clotting Disorder

    Shanghai RAAS Blood Products Gets Trial Approval for Blood Clotting Disorder

    marketscreener·
    SZ
    002252
    +0.30%
    marketscreener·
    SZ
    002252
    +0.30%

    Shanghai RAAS: Executives have increased their holdings by 0.014% of shares

    Shanghai RAAS announced that Vice Chairman and General Manager Xu Jun, along with some directors and all senior management personnel, cumulatively increased their holdings of the company's shares by 946,000 shares through centralized bidding from September 10 to October 30, 2025, accounting for 0.014% of the company's total share capital, with an increase amount of 6.4828 million yuan; this increase plan was originally scheduled to be implemented within 6 months starting from September 5, 2025, with a planned increase amount of no less than 6 million yuan, which has now been completed

    Zhitong·
    SZ
    002252
    +0.30%
    Zhitong·
    SZ
    002252
    +0.30%

    Shanghai RAAS: The net profit for the third quarter was 441 million yuan, a decrease of 26.16%

    Shanghai RAAS announced that its revenue for the third quarter was 2.139 billion yuan, an increase of 3.72% year-on-year; net profit was 441 million yuan, a decrease of 26.16%. Revenue for the first three quarters was 6.091 billion yuan, a year-on-year decrease of 3.54%; net profit was 1.471 billion yuan, a year-on-year decrease of 19.97%

    Zhitong·
    SZ
    002252
    +0.30%
    Zhitong·
    SZ
    002252
    +0.30%

    Shanghai RAAS's controlling shareholder Haiyingkang has completed an increase in holdings, with a total investment amount of approximately 500 million yuan

    According to the Zhitong Finance APP, Shanghai RAAS announced that its controlling shareholder Haiyingkang has completed the plan to increase its shareholding in the company. Haiyingkang has cumulatively increased its shareholding by 72.9353 million shares through centralized bidding on the Shenzhen Stock Exchange, accounting for 1.10% of the company's total share capital, with a total investment amount of approximately 500 million yuan (excluding transaction fees)

    Zhitong·
    SZ
    002252
    +0.30%
    Zhitong·
    SZ
    002252
    +0.30%

    Shanghai RAAS: Executives plan to increase holdings by 6 million yuan

    Shanghai RAAS announced that the company's Vice Chairman and General Manager Jun Xu and 6 other senior management personnel plan to increase their holdings of the company's shares through centralized bidding within 6 months from the date of the announcement, with a total increase amount of no less than RMB 6 million, funded by self-raised funds; this increase plan does not set a price range, and if there is a suspension during the implementation period, it will be postponed until after the resumption of trading

    Zhitong·
    SZ
    002252
    +0.30%
    Zhitong·
    SZ
    002252
    +0.30%
    © 2025 Longbridge｜Disclaimer